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Background and objective: Diffuse intrinsic pontine glioma (DIPG) is a lethal brainstem 
tumor in children. Dendritic cells (DCs) have T-cell stimulatory capacity and, therefore, 
potential antitumor activity for disease control. DCs vaccines have been shown to reacti-
vate tumor-specific T cells in both clinical and preclinical settings. We designed a phase 
Ib immunotherapy (IT) clinical trial with the use of autologous dendritic cells (ADCs) 
pulsed with an allogeneic tumors cell-lines lysate in patients with newly diagnosed DIPG 
after irradiation (radiation therapy).
Methods: Nine patients with newly diagnosed DIPG met enrollment criteria. Autologous 
dendritic cell vaccines (ADCV) were prepared from monocytes obtained by leukapheresis. 
Five ADCV doses were administered intradermally during induction phase. In the absence 
of tumor progression, patients received three boosts of tumor lysate every 3 months during 
the maintenance phase.
results: Vaccine fabrication was feasible in all patients included in the study. Non-
specific KLH (9/9 patients) and specific (8/9 patients) antitumor response was identified 
by immunologic studies in peripheral blood mononuclear cells (PBMC). Immunological 
responses were also confirmed in the T lymphocytes isolated from the cerebrospinal fluid 
(CSF) of two patients. Vaccine administration resulted safe in all patients treated with this 
schema.
Conclusion: These preliminary results demonstrate that ADCV preparation is feasible, 
safe, and generate a DIPG-specific immune response detected in PBMC and CSF. This 
strategy shows a promising backbone for future schemas of combination IT.
Keywords: immunotherapy, dendritic, cell, vaccination, diffuse intrinsic pontine glioma
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BaCKGrOUnD
Diffuse intrinsic pontine glioma (DIPG) accounts for the vast 
majority of brainstem tumors in children. Upfront focal irradia-
tion is the only effective palliative therapy, achieving clinical and 
radiologic response in the majority of patients. Unfortunately, irre-
versible tumor re-growth is the rule during the following 2 years 
after initial presentation (1). DIPG molecular characterization has 
unveiled specific alterations and key biologic pathways showing 
that we are not in front of just one entity, but of a heterogeneous 
group of tumors that share clinical and radiologic characteristics 
and similar poor prognosis. These molecular alterations are now 
starting to be translated into targeted therapies (2–5). Also, new 
delivery systems that attempt to circumvent the blood–brain bar-
rier are being tested (6) and exciting preclinical and clinical pro-
jects—including IT—may change soon our therapeutic approach 
to this infiltrative glioma (7–12). Immunotherapy (IT) is gaining 
popularity as a potential efficacious therapeutic option for central 
nervous system (CNS) aggressive glial tumors both in adults and 
children (13). Several decades ago, different groups reported that 
gliomas promote both local and systemic immunosuppression 
to a certain degree. Numerous cell-based pathways of immu-
nosuppression were first identified in glioblastoma multiforme, 
and these observations collectively support the hypothesis that 
immune system modulation could have therapeutic potential. 
The CNS, historically considered as immune privileged and 
“protected” site, is a dynamic immunological environment in 
which astrocytes, microglia, and a variety of infiltrating immune 
cells play a major role in these structures during host immunity 
to antigens, representing a valuable weapon to fight effectively 
cancer maintenance and progression (13, 14). Importantly, these 
strategies may be of particular relevance for non-resectable, 
radio-resistant, invasive, migratory, and aggressive gliomas. Even 
though DIPG’s “epicenter” is identified radiologically at diagnosis 
in the pons, is now well recognized that early or late microscopic 
and/or macroscopic dissemination plays a key role in tumor 
progression and dismal outcome (15). Consequently, the future 
potential effective therapeutic schema for DIPG will surely need 
a mechanism that secures “whole CNS control,” since we need 
to address its dissemination capacity from diagnosis, even in the 
absence of macroscopic disease by imaging.
Currently, two different IT strategies are being tested 
specifically for DIPG in early clinical trials (clinicaltrials.gov: 
NCT02960230 and NCT02359565). There is enough accumu-
lated data that support the idea that Autologous dendritic cell 
vaccine (ADCV) can satisfactory induce maintained antitumor 
immunological responses. These IT approach has achieved 
encouraging clinical and radiologic results in cases with advanced 
cancers (16–19). We expect that dendritic cells (DCs) loaded with 
a variety of DIPG tumor antigens, will have the ability to induce 
antitumor immune responses in patients with newly diagnosed 
DIPG after upfront irradiation. Based on our accessibility to 
robust molecularly tested DIPG cell lines immortalized in our 
laboratory, we decided to explore the potential use of autologous 
dendritic cells (ADCs) pulsed with an allogeneic tumor cell-lines 
lysate (ATCL) rich in tumor antigens and potentially neo-antigens 
in patients with newly diagnosed DIPG after upfront irradiation. 
The principal objective of this pilot study was to establish the 
feasibility of preparation and safety of intradermic administra-
tion of ADCVs in patients with newly diagnosed DIPG after 
radiation therapy (RT). Additionally, to evaluate the non-specific 
and specific antitumoral immune response generated.
PaTiEnTS anD METHODS
Study Design
This is an institutional phase Ib trial at Hospital Sant Joan de Déu, 
in collaboration with Hospital Clínic, both in Barcelona, Spain. The 
ethics committee at both institutions and the Spanish regulatory 
Agency for novel products and medications approved the clinical 
trial prior patient accrual (AEMPS; PEI 15-215, and PEI 15-216, 
clinicaltrials.gov: NCT02840123). Parents or legal guardians 
provided written informed consent at patient inclusion. Eligible 
patients included cases with newly diagnosed non-metastatic 
DIPG based upon radiologic criteria which showed clinical and 
radiologic response to upfront RT. Tumor biopsy was not manda-
tory for trial inclusion. A Lansky performance of 50 or above, 
life expectancy of more than 8 weeks and basic hematologic and 
metabolic parameters within normal limits were mandatory. 
Exclusion criteria included tumor progression after RT, meta-
static disease at diagnosis or after RT and steroids dependency 
for neurologic stability. Other exclusion criteria included active 
or uncontrolled infections and concurrent immunosuppressive 
treatment or infection by HIV, HBV, or HCV.
Patient’s DCs were derived from monocytes obtained by leu-
kapheresis at diagnosis or at completion of RT once steroids had 
been discontinued. These monocytes-derived DCs were loaded 
with an ATCL composed of eight cell lines obtained and matured 
ex vivo from five patients treated in the past in our institution 
with H3K27 mutated DIPG. Patients included in the trial were 
planned to receive five intradermal injections (0.4 ml/injection) 
containing 10 ×  106 mature ADCs previously pulsed with the 
above mentioned tumor lysate. The first dose administration 
was planned 3–6 weeks after the completion of RT. Following 
doses were planned in an every other week basis. Three months 
after the last dose of the induction phase and in the absence 
of clinical or radiologic progression, patients re-started therapy 
Abbreviations: AEMPS, Agencia Española del Medicamento y Productos 
Sanitarios (Spanish regulatory agency for ATM); ACVR1, activin A receptor, 
type I; ATCL, allogeneic tumor cell-lines lysate; ADC, autologous dendritic cell; 
ADCV, autologous dendritic cell vaccines; AE, adverse event; APC, antigen-
presenting cells; BBB, blood–brain barrier; CED, convection-enhanced delivery; 
CFSE, 5,6-carboxyfluorescein diacetate succinimidyl ester; CNS, central nervous 
system; CSF, cerebrospinal fluid; CT, computed tomography; CTL, cytotoxic 
T lymphocytes; DC, dendritic cells; DIPG, diffuse intrinsic pontine glioma; DNFB, 
dinitrofluorobenzene; EFS, event-free survival; GAAs, glioma-associated antigens; 
GM-CSF, granulocyte macrophage colonies stimulating factor; GMP, good manu-
facturing practices; GBM, glioblastoma multiforme; HGGs, high-grade gliomas; 
IT, immunotherapy; MHC, major histocompatibility complex; NK, natural killer; 
NKT, natural killer/T-cells; PBS, phosphate-buffered saline; PICU, pediatric inten-
sive care unit; OS, overall survival; PBMC, peripheral blood mononuclear cells; 
PDGFRA, platelet-derived growth factor receptor α; RT, radiation therapy; WHO, 
World Health Organization; WBC, white blood cells.
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with boosts of DIPG ATCL as a maintenance phase for a total 
of three doses.
Tumor Samples and Preparation of aTCl
Tumor Samples
Primary tumor-sphere cultures from five DIPG patients 
named after the codes HSJD-DIPG-007, HSJD-DIPG-008, 
HSJD-DIPG-012, HSJD-DIPG-013, and HSJD-DIPG-014 were 
established from fresh tumor fragments. In brief, tumor tissues 
were disaggregated using a mixture of collagenase (5 mg/mL) 
and DNAse (400 Kunitz Units/mL) from Sigma (St. Louis, MO, 
USA) at 37°C during 5 min to obtain single cell suspensions. 
Cells were cultured in a mixture of Dulbecco’s modified Eagle’s 
medium/F-12 and neurobasal-A medium at a 1:1 ratio with 
HEPEs, sodium pyruvate, non-essential aminoacids solution, 
glutamax, and antibiotic-antimycotic supplemented with 2% 
B27 (all from Life Technologies, Grand Island, NY, USA), and 
growth factors EGF (20 ng/mL), bFGF (20 ng/mL), PDGF-AA, 
and PDGF-BB (10  ng/mL), all from Peprotech (Rocky Hill, 
NJ, USA) and 2  µg/mL heparin (Sigma). Additionally, cells 
HSJD-DIPG-007, HSJD-DIPG-012, and HSJD-DIPG-013 were 
cultured in the absence of supplements and growth factors and 
adding 10% fetal bovine serum to establish adherent cultures. 
Thus, five tumor-sphere cultures and three adherent cultures 
were used to produce the final eight ATCL.
Preparation of ATCL
Diffuse intrinsic pontine glioma cell lines were pooled together 
and 50% of these pooled cells were treated with dinitrofluor-
obenzene (DNFB) for 15 min at room temperature to increase 
immunogenicity. After extensive washing with phosphate-
buffered saline (PBS), pooled and DNFB treated cells were suc-
cessively incubated for five cycles of 1 min in liquid nitrogen and 
at 37°C freezing and thawing to produce the cell lysate. Aliquots 
of 1 mL of this 10 × 106 cells/mL of PBS were irradiated at 25 kGy 
in order to sterilize the product. The absence of viral, bacterial, or 
any cell growth was confirmed in the final product.
Preparation of aDCVs
After inclusion in the study, leukapheresis was performed to 
obtain peripheral blood leukocytes. Autologous monocytes 
were selected by adherence to plastic, and then differentiated 
to DCs for 7  days in synthetic X-VIVO 15 media (Lonza, 
Walkersville, MD, USA) supplemented with 2% autologous 
serum and differentiation cytokine mix [800 U/ml granulocyte-
macrophage colonies stimulating factor (Miltenyi Biotech, 
Bergisch Gladbach, Germany)  +  500  U/ml IL-4 (Miltenyi 
Biotec, Bergisch Gladbach, Germany)]; an additional 24 h in a 
maturation cytokine mix [10 ng/ml TNF-α (Miltenyi Biotech, 
Bergisch Gladbach, Germany)  +  10  ng/ml IL1-β (Miltenyi 
Biotech, Bergisch Gladbach, Germany)  +  10  ng/ml IL-6 
(Miltenyi Biotech, Bergisch Gladbach, Germany) +  1  µg/ml 
prostaglandin E2 (PGE2; Dinoprostona, Pfizer, New York, NY, 
USA) + 20 µg/ml poly(I:C) (Hiltonol®; Oncovir Inc, Washington 
DC, USA) (courtesy of Dr. Andres Salazar)] in the presence 
of ATCL plus KLH 10 µg/ml (IMMUCOTHEL® from Biosyn) 
using good manufacturing practice standard procedures. 
DC maturation was confirmed by assessing increases in the 
immunofluorescence of CD80, CD83, and CD86 (all from BD 
Bioscience, San Diego, CA, USA) and HLA-DR (BD Bioscience, 
San Diego, CA, USA), and purity determined by the absence of 
CD3 (T  lymphocytes) (BD Bioscience, San Diego, CA, USA), 
CD14 (Monocytes) (BD Bioscience, San Diego, CA, USA), 
and CD19 (B lymphocytes) (BD Bioscience, San Diego, CA, 
USA). Flow cytometry analysis was performed using FACS 
Canto II and FACSDIVA® software (BD Bioscience, San Diego, 
CA, USA). Release criteria included >80% CD80+, CD86+ and 
negative microbial test (sterility and mycoplasma detection) 
according to European Pharmacopeia.
immunological Monitoring
Peripheral blood mononuclear cell (PBMC) and serum were 
collected every 2  weeks, starting baseline and prior to each 
vaccine dose during the induction phase. PBMCs were labeled 
with 5,6-carboxyfluorescein diacetate succinimidyl ester (CFSE) 
to evaluate cell division. To determine the effect of ADCVs in 
the non-specific and specific antitumor immune response, the 
presence of tumor lysate specific T-cells was evaluated, before 
and after treatment, incubating PBMC with KLH or ATCL, 
respectively. Plates were incubated in a humid atmosphere of 5% 
CO2 at 37°C for 7  days. T-cell proliferation (cell dilution) was 
evaluated by a flow cytometry-based assay and quantified as the 
percentage of proliferating (CFSE-diluted) cells. When present, 
T-cells were expanded from cerebrospinal fluid cerebrospinal 
fluid (CSF) (taken prior to first dose of vaccine, 2  weeks after 
dose 4 and dose 5) by using anti-CD3-CD28 beads and rhIL-2. 
Expanded T-cells were incubated with autologous mature DCs 
loaded with KLH or tumor cell line lysate with the same goal as 
described above. Cells were incubated in a humid atmosphere of 
5% CO2 at 37°C for 7 days. Eighteen hours before termination 
of culture, each well received 0.5 μCi of methyl-3H-thymidine 
at 2 Ci/mmol (TRA310; Amersham Biosciences, Little Chalfont, 
UK). Uptake of thymidine into DNA was determined using a cell 
harvester (Perkin Elmer, Massachusets, USA). We calculated the 
geometric mean of three replicates.
rESUlTS
Patient Characteristics
To date, 20 patients were evaluated for eligibility for the trial. 
Eleven patients were not eligible. All of them were not eligible due 
to local or metastatic tumor progression at the end of RT. Nine 
patients between 4 and 10 years of age were enrolled in the trial. 
Demographic, clinical, and tumor tissue data are summarized in 
Table 1.
aDCVs Preparation
All patients included in the trial went successfully through 
leukapheresis. No complications secondary to the procedure 
were reported. Enough mononuclear cells were recovered for the 
preparation of the five doses needed for the induction phase for 
all cases.
FiGUrE 2 | Consort diagram.
FiGUrE 1 | Therapeutic schema.
TaBlE 1 | Patients characteristics.
Patient iD age (years) Sex Biopsy Histologic diagnosis K27M status radiation therapy (dose) Steroids discontinued prior 
to enrollment
DIPG-DC001 7 F N N/A N/A Y (54 Gy) Y
DIPG-DC002 5 F Y K27M Midline diffuse glioma K27M H3.3 mutated Y (54 Gy) Y
DIPG-DC003 7 F Y K27M Midline diffuse glioma K27M H3.3 mutated Y (54 Gy) Y
DIPG-DC004 7 M N N/A N/A Y (54 Gy) Y
DIPG-DC006 5 F Y High-grade glioma (HGG).  
IHC suggest WT K27M
N/A Y (54 Gy) Y
DIPG-DC007 5 F N N/A N/A Y (54 Gy) Y
DIPG-DC008 10 F Y K27M Midline diffuse glioma K27M H3.3 mutated Y (54 Gy) Y
DIPG-DC009 4 M N N/A N/A Y (39 Gy)—hypofractionated Y
DIPG-DC010 4 F Y HGG K27M WT Y (54 Gy) Y
Y, yes, N, no, IHC, immunohistochemistry, WT, wild type.
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Therapy administered
All patients received upfront focal irradiation as part of DIPG 
standard of care. Clinical and radiologic response was confirmed 
prior to study entry and distant dissemination was ruled out by 
brain and spine MRI.
Induction Phase
In the absence of new clinical symptoms, patients received five 
outpatient ADCVs doses during this phase (AEMPS PEI 15-215). 
Forty-four dosages of ADCVs were administered. One patient 
did not receive the fifth dose of the induction phase due to tumor 
progression.
Maintenance Phase
Three months after the last induction phase dose—in the absence 
of tumor progression—three boost dosages of ATCL (AEMPS 
PEI 15-216) 3 months apart were administered intradermically 
(Figure 1).
Up to the date of this report, four dosages of ATCL have been 
administered to three patients and three patients are still on trial 
within the maintenance phase (Figure 2).
Toxicity
Intradermally administration of ADCVs was overall well toler-
ated. Therapy was administrated in an outpatient regimen with 
no significant adverse events (AEs) identified. Although mild 
local pain and/or mild itching were reported during intrader-
mally dosages administration, no relevant systemic symptoms 
were reported after vaccination. Mild headaches and nausea 
were reported in a few dosages in most patients. Laboratory 
abnormalities were mild and no clinically relevant. Patient 
DIPG-DC006 developed an intratumoral hemorrhage after the 
second dose of the induction phase. Neurologic deterioration 
prompted delayed administration of doses 3 and 4. Patient 
DIPG-DC010 developed recurrent biopsy-tract infections: the 
first episode was recorded prior to the initiation of IT. When 
enrolled in the study, infection was under control. Thereafter, 
we do not think the infection is related to the ADCVs. Table 2 
TaBlE 2 | Adverse events (AEs).
Patient iD aE CTCaE grade (max. grade)
DIPG_DC001 Headaches 1
Nausea 1
Anemia 1
DIPG_DC002 Headaches 1
Nausea 1
Vomiting 1
Anemia 1
Leukopenia 1
DIPG_DC003 Headaches 2
Nausea 2
Vomiting 2
Anemia 1
Leukopenia 1
DIPG_DC004 Headaches 1
Vomiting 1
Leukopenia 1
Thrombocytopenia 1
DIPG_DC006 Headaches 2
Alopecia 1
Anemia 1
Leukopenia 1
DIPG_DC007 Nausea 1
Vertigo 2
Anemia 1
Leukopenia 1
DIPG_DC008 Headaches 1
Nausea 1
Leukopenia 1
Neutropenia 1
Vomiting 1
DIPG_DC009 Headaches 1
Vomiting 1
Leukopenia 1
DIPG_DC010 Headaches 1
Nausea 1
Osteomielitis 3
Anemia 1
Leukopenia 1
Lymphopenia 1
Hypokalemia 1
Hypertension 2
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shows the list of AEs observed during therapy for all the patients 
enrolled.
Vaccines Characterization
Autologous dendritic cell vaccines were fabricated with no 
complications in all nine patients included in the study. As 
represented in Figure 3A, ADCV production fulfilled the release 
criteria showing an increased expression of costimulatory 
(CD80), maturation (CD83), antigen presenting [major histo-
compatibility complex (MHC) class II], and cytokine receptor 
(CCR7) molecules on DCs surface membrane when compared to 
immature DCs phenotype. Interestingly, not only percentage, but 
also the intensity of molecules (MFI) (Figure 3B) was increased 
in the vaccine product. Routinely, the viability of ADC was up to 
80% and purity above 90%.
immunologic response in Peripheral 
Blood
In order to monitor the effect of ADCVs administration in 
patients included in the trial, induction of antigen-specific T-cells 
was studied by a proliferation assay based on CFSE-dilution, 
comparing non-specific (against KLH) and specific response to 
ATCL. Patients treated with ADCVs increased KLH-specific and 
ATCL specific T-cell response detected by T-cell proliferation 
(CFSE-dilution) (Table 3). It is important to highlight the recog-
nition of ATCL in eight of nine patients at some point during 
ADCV therapy administration. The induction of KLH-specific 
response in the majority of the patients indicates the potency 
of ADCV to generate an immune response in the patients. Of 
note, as shown in the same table, case DIPG-DC003 showed 
pre-vaccination reactivity. This could indicate spontaneous self-
vaccination against tumor antigens in the case of the tumor lysate 
as stimuli, while the lowest reactivity against KLH (never present 
in non-vaccinated individuals) suggests non-specific intercurrent 
stimuli (i.e., infection) that could induce a basal reactivity.
immunologic response in the CSF
With the intention of identifying a closer and more suitable sur-
rogate marker for the immune response generated by vaccination 
in the tumor environment, we collected CSF by serial spinal taps 
from the patients included in the study. If identified, T-cells were 
expanded in vitro after CD3–CD28 stimulation in the presence 
of rhIL-2. We were able to expand and analyze the specificity of 
response from T-cells isolated from two patients (DIPG-DC003 
and DIPG-DC009). Interestingly, after ADCV administration, 
KLH responding T-cells in the CSF were detected in both patients 
measured by cell proliferation (Figure  4A) IFN-γ production 
(Figure 4B). For DIPG-DC003, ATCL specific T-cells were also 
identified in the CSF collected 2 weeks after the fifth ADCV dose 
administration showing specific anti-DIPG response.
DiSCUSSiOn
This is, to our knowledge, the first clinical report of ADCVs 
administration using a DIPG ATCL to pulse the ADCs, after 
upfront RT in a homogeneous cohort of patients with newly 
diagnosed DIPG. Our findings show feasibility, reasonable safety 
of this therapeutic approach, as well as evidence of non-specific 
and specific antitumor immunological response generated in 
treated patients.
With standard therapy, the mean overall survival (OS) reported 
in DIPG is approximately 8–11  months, and the majority of 
patients succumb to disease within the first 2 years after diagnosis. 
Focal irradiation at diagnosis and re-irradiation at progression 
benefit a proportion of patients, but life expectancy is overall poor 
(20, 21). DIPG molecular characterization has shown unique 
abnormalities when compared with other non-midline pediatric 
high-grade glioma (HGG) and to adult HGG. Thus, we understand 
now DIPG not as a single entity, but as a heterogeneous group of 
tumors that develop in the ventral pons of school-aged children 
and harbors specific genetic (i.e., TP53, PDGFRA, ACVR1, and 
FGFR1) and more importantly epigenetic (i.e., K27M H3.3 and 
FiGUrE 3 | Characterization of dendritic cells (DCs) vaccines. (a) Increased expression of CD80, CD83, MHC class II, and CCR7 molecules on DCs surface 
membrane of autologous dendritic cell (ADC) compared to immature DC used as negative control. (B) Increased intensity of molecules (MFI) of ADC after stimulation 
compared to immature DC used as negative control.
TaBlE 3 | Percentage (%) of proliferating T-cells from PBMCs labeled with 5,6-carboxyfluorescein diacetate succinimidyl ester-dilution in response to tumor cell line 
lysate or KLH after substraction of signal in unstimulated control.
Pre-vaccination Post-1 induction Post-2 induction Post-3 induction Post-4 induction
Tumor lysate KlH Tumor lysate KlH Tumor lysate KlH Tumor lysate KlH Tumor lysate KlH
DIPG-DC001 – – – – 3.2% 3.5% – – – –
DIPG-DC002 – – 4% – – 1.4% – 3.6% – –
DIPG-DC003 33%a 3.5%a – 26% – 16.1% – 3.7% 3.4% 14.7%
DIPG-DC004 – – – 7.7% 7.1% 57.8% 2.4% 2.9% 3.6% 7.6%
DIPG-DC006 – – – – 8.3% 11.6% 2.6% 1.2% 9.6% 42%
DIPG-DC007 – – – – – – – 17 3.3 9.3
DIPG-DC008 – – – 20% nd nd – – – –
DIPG-DC009 – – – 18.6% – 6.3% 31.7% 33% – 18.3%
DIPG-DC010 – – – 1.5% – 1.5% – 8.8% 4.3% 26.6%
nd, not determined; (–), no proliferation.
aThis pre-vaccination reactivity could indicate spontaneous self-vaccination against tumor in the case of lysate as stimuli, while the lowest reactivity against KLH (never present in 
non-vaccinated individuals) suggests non-specific intercurrent stimuli (i.e., infection) that could induce a basal reactivity.
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H3.1 variants) alterations (22). This molecular variability may 
explain different tumor behavior and response to RT and will be 
paramount for the design of future clinical trials. However, this 
new bulk of knowledge has not impacted significantly the OS. 
Additionally, current strategies including focal RT or newer deliv-
ery systems (e.g., convection-enhanced delivery) target the bulk 
of tumor burden. However, it has been well recognized that tumor 
migration and dissemination occurs early during DIPG course 
(15). Therefore, potentially effective strategies should aim to reach 
not only the macroscopically infiltrated pons but to identify and 
exterminate all malignant cells within the CNS.
Immunotherapy has recently gained popularity in a number 
of refractory adult solid tumors. In terms of effectiveness, CNS 
tumors disease control lags behind for a number of reasons. 
However, more and more IT seems to be a promising part of the 
armamentarium necessary to control and eradicate invasive glio-
mas (13). Therapeutic vaccination relies on the patient’s immune 
system to react to an injected tumor vaccine. ADCs are a subset 
of white blood cell, and play a key component to most aspects 
of adaptive immunity due to their central role as specialized 
antigen-presenting cells in the initiation and propagation phase 
of T-cell responses (18). Typically DCs reside as inactivated and 
FiGUrE 4 | Isolated and expanded T-cell obtained from CFS. (a) Antigen specificity of T cell from CSF was evaluated by cell proliferation (cpm indicates thymidine 
incorporation; cpm = counts per million) in response to KLH or tumor cell lines lysate. (B) T cell activation was measured by cytokine production (IFN-γ) in response 
to KLH or tumor cell lines lysate compared to negative.
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immature state in organs and tissues at the interface of potential 
pathogen entry sites. After a recognized stimulus, they upregulate 
a cascade of events involving mostly chemokine receptors, which 
guide them to draining lymph nodes. There, the already mature 
DCs are capable of generating primary T-cell responses due to 
their high levels of MHC, adhesion and costimulatory molecule 
expression. Of note, DCs are able to present and cross-present 
the antigenic peptides in the context of both MHC Class II and 
Class I molecules, respectively, promoting CD4+ T and CD8+ 
cells, both fundamental for an effective cell-mediated immune 
response. DCs are also strong activators of natural killer and 
NKT  cells, linking effectively the innate and adaptive immune 
responses. Therefore, both tumor cells with and without expres-
sion of MHC molecules can theoretically be eradicated (17, 23). 
HGGs have been shown to express an impressive collection of 
glioma-associated antigens (GAAs). Targeting specific or groups 
of GAAs using selected peptides (24) would inherently lead to 
immune escape because of the positive clonal selection of anti-
gen-loss variants: those tumor cell clones that do not express the 
particular, targeted GAA or the clones that go through immune-
editing and loose the expression of the antigen, will potentially 
escape from the immune rejection generated by the vaccination 
and thus have an important proliferation advantage and selection 
as compared to the cell clones that do express the targeted GAA. 
This is the main reason to use whole ATCL of different cell lines 
as a source of GAAs to load DCs. Our expectation was to generate 
a vast immune response against the most immunogenic and com-
mon DIPG antigens present in the ATCL. Vaccines generation 
was successfully achieved in all patients included in the trial. 
Our ADCV therapy was overall well tolerated and no remarkable 
clinical or laboratory toxicity was identified. The administration 
of dosages was ambulatory, offering an optimal quality of life 
for patients included in the trial with limited ambulatory visits 
or admission for inpatient therapy. Of note, patient DIPG006 
developed an intratumoral hemorrhage after the second dose 
of ADC which prompted admission to the pediatric intensive 
care unit for respiratory support due to decrease in the level of 
consciousness. Due to neurologic deterioration, systemic steroids 
were administered for 3 weeks and the patient rapidly improved 
after a few days. It is unlikely that this hemorrhage was secondary 
to the ADCV, since it occurred after dose 2 when no antitumor 
response was identified in PBMCs. Additionally; there have been 
reports of spontaneous tumoral bleeds throughout DIPG disease 
course. Interestingly, this patient developed a strong vaccine 
immune response with no apparent new neurologic symptoms.
Our results show that vaccines preparation was feasible 
in all patients and doses administrations were well tolerated. 
Non-specific and antitumor lysate specific cellular response was 
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obtained in PBMCs in the majority of patients included in the 
trial during therapy. We could identify a similar response in 2/9 of 
patients’ CSF, one of them showing specific anti-DIPG response. 
We speculate we could only identify two cases of response in the 
CSF given the low number of lymphocytes in this compartment. 
In summary, this ongoing trial demonstrates the feasibility of 
specific ADCV preparation, acceptable safety and promising 
preliminary specific antitumor immunoreactivity in response 
to ADCV. Clinical and radiologic correlation will be reported 
when all data are available. Additionally, it is very interesting 
the identification of HLA-A2-restricted immunogenic peptide 
derived from the K27M H3.3 mutation (25). The recognition by 
CTLs from patients immunized opens the possibility to specifi-
cally target the cells harboring the mutation. Nonetheless, there 
is clearly room for improvement for approaching DIPG with IT 
strategies. The immunological responses shown in our study can 
be surely substantiated by incorporating strategies to prevent 
immune resistance or editing/escape, such as the concomitant 
administration of immune checkpoint inhibitors that can poten-
tiate and maintain the immune response generated by the ADCV.
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